Oppenheimer Asset Management Inc. Has $1.79 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Oppenheimer Asset Management Inc. boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIXFree Report) by 12.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,929 shares of the company’s stock after buying an additional 1,736 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Neurocrine Biosciences were worth $1,792,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Norges Bank acquired a new stake in Neurocrine Biosciences in the fourth quarter valued at $111,786,000. BlackRock Inc. increased its holdings in Neurocrine Biosciences by 6.6% in the first quarter. BlackRock Inc. now owns 13,466,650 shares of the company’s stock valued at $1,363,094,000 after purchasing an additional 838,997 shares during the period. Braidwell LP acquired a new stake in Neurocrine Biosciences in the first quarter valued at $77,615,000. Woodline Partners LP increased its holdings in Neurocrine Biosciences by 189.0% in the second quarter. Woodline Partners LP now owns 1,152,189 shares of the company’s stock valued at $108,651,000 after purchasing an additional 753,495 shares during the period. Finally, Ieq Capital LLC acquired a new stake in Neurocrine Biosciences in the second quarter valued at $45,384,000. Institutional investors own 93.54% of the company’s stock.

Insiders Place Their Bets

In other news, insider Darin Lippoldt sold 10,919 shares of the company’s stock in a transaction that occurred on Monday, November 27th. The stock was sold at an average price of $112.27, for a total value of $1,225,876.13. Following the completion of the sale, the insider now directly owns 35,882 shares in the company, valued at $4,028,472.14. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Darin Lippoldt sold 10,919 shares of the firm’s stock in a transaction dated Monday, November 27th. The shares were sold at an average price of $112.27, for a total transaction of $1,225,876.13. Following the completion of the sale, the insider now directly owns 35,882 shares in the company, valued at $4,028,472.14. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Jude Onyia sold 2,331 shares of the stock in a transaction that occurred on Wednesday, November 29th. The shares were sold at an average price of $113.57, for a total transaction of $264,731.67. Following the completion of the sale, the insider now directly owns 11,732 shares of the company’s stock, valued at approximately $1,332,403.24. The disclosure for this sale can be found here. Insiders have sold a total of 270,631 shares of company stock valued at $35,043,864 in the last 90 days. 4.60% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Wells Fargo & Company lifted their price objective on Neurocrine Biosciences from $110.00 to $127.00 and gave the stock an “equal weight” rating in a research report on Wednesday, December 13th. BMO Capital Markets cut their price target on Neurocrine Biosciences from $111.00 to $100.00 and set a “market perform” rating on the stock in a report on Friday, November 10th. The Goldman Sachs Group upped their price objective on shares of Neurocrine Biosciences from $134.00 to $153.00 and gave the stock a “buy” rating in a report on Thursday, January 25th. StockNews.com cut shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, January 19th. Finally, Piper Sandler raised their price target on shares of Neurocrine Biosciences from $95.00 to $100.00 and gave the company a “neutral” rating in a research report on Wednesday, November 1st. Six research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $134.69.

Get Our Latest Analysis on NBIX

Neurocrine Biosciences Price Performance

Shares of NBIX stock opened at $142.96 on Wednesday. The stock has a 50 day simple moving average of $129.58 and a 200-day simple moving average of $116.49. The company has a market cap of $14.05 billion, a price-to-earnings ratio of 76.86, a PEG ratio of 0.75 and a beta of 0.25. Neurocrine Biosciences, Inc. has a 1-year low of $89.04 and a 1-year high of $143.35.

Neurocrine Biosciences Company Profile

(Free Report)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.

See Also

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIXFree Report).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.